WEEKEND NEWS
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg/kg arm, 70% for 2.7 mg/kg arm
▪️Median rPFS: ~8.5 months (2.0 mg/kg), ~7.5 months (2.7 mg/kg)
▪️Confirmed objective response rate: 20% (2.0 mg/kg), 40.6% (2.7 mg/kg)
▪️Median 6 doses administered, extending treatment duration compared to Phase 1
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg/kg arm, 70% for 2.7 mg/kg arm
▪️Median rPFS: ~8.5 months (2.0 mg/kg), ~7.5 months (2.7 mg/kg)
▪️Confirmed objective response rate: 20% (2.0 mg/kg), 40.6% (2.7 mg/kg)
▪️Median 6 doses administered, extending treatment duration compared to Phase 1
The company expects to have mature median rPFS data by early 2025, which will inform future development decisions.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1631Followers
89Following
12KVisitors
Follow